Teoxane issues competing buyout bid for Revance and its Botox rival

Nicole DeFeudis

Editor

Revance Therapeutics’ contract dispute with a Swiss partner has caused hiccups in its plan to be acquired by Crown Laboratories. Now that partner says it …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Teoxane issues competing buyout bid for Revance and its Botox rival

Nicole DeFeudis

Editor

Sign up to read this article for free.

Vir’s early T cell engager data offer first look at cancer pivot, stock jumps

Updated: Galapagos to split into two companies, slash headcount as it eyes turnaround

ARCH, F-Prime and Mubadala pump $200M into former Denali programs

Maze files for first biotech IPO of 2025, following $115M funding boost

Every FDA drug approval from 2024: Fewer nods, but long-awaited treatments cross the finish line

Sana’s stock soars on new cell therapy data; UniQure’s $75M offering

Teox­ane is­sues com­pet­ing buy­out bid for Re­vance and its Botox ri­val

Nicole DeFeudis

Editor

Sign up to read this article for free.

more like this

Vir’s ear­ly T cell en­gager da­ta of­fer first look at can­cer piv­ot, stock jumps

Up­dat­ed: Gala­pa­gos to split in­to two com­pa­nies, slash head­count as it eyes turn­around

ARCH, F-Prime and Mubadala pump $200M in­to for­mer De­nali pro­grams

Maze files for first biotech IPO of 2025, fol­low­ing $115M fund­ing boost

Every FDA drug ap­proval from 2024: Few­er nods, but long-await­ed treat­ments cross the fin­ish line

Sana’s stock soars on new cell ther­a­py da­ta; UniQure’s $75M of­fer­ing

Teoxane issues competing buyout bid for Revance and its Botox rival

Vir’s early T cell engager data offer first look at cancer pivot, stock jumps

Updated: Galapagos to split into two companies, slash headcount as it eyes turnaround

ARCH, F-Prime and Mubadala pump $200M into former Denali programs

Maze files for first biotech IPO of 2025, following $115M funding boost

Every FDA drug approval from 2024: Fewer nods, but long-awaited treatments cross the finish line

Sana’s stock soars on new cell therapy data; UniQure’s $75M offering